Features include: Histiocytoma.

CREB1 encodes cAMP responsive element binding protein 1 (327 aa). Phosphorylation-dependent transcription factor that stimulates transcription upon binding to the DNA cAMP response element (CRE), a sequence present in many viral and cellular promoters. Highest expression in Cells EBV-transformed lymphocytes (20.6 TPM) and Cervix Ectocervix (18.2 TPM).

Histiocytoma, Angiomatoid fibrous is associated with mutations in the CREB1 gene on chromosome 2.

The CREB1 protein participates in CREB1 gene expression is stimulated by MECP2 pathway.

CREB1 is classified as a druggable target (Clinically Actionable, Kinase, and Transcription Factor categories) with score 4.7.

Genetic testing for CREB1 is available. Testing is considered confirmatory for diagnosis.

Biomarker and diagnostic research for histiocytoma, Angiomatoid fibrous has been reported in the published literature.

Estimated prevalence: Unknown (Unknown prevalence).

2 clinical trials registered, 1 recruiting. Interventions under study include drug therapy and procedural interventions. Pipeline includes 1 PHASE2, 1 PHASE1. Research is primarily sponsored by academic and government institutions.

45 publications have been identified in PubMed for histiocytoma, Angiomatoid fibrous. Research spans Case Report / Case Series (60%), Review / Meta-Analysis (22%), and Basic Science / Preclinical (9%).